New England Journal of Medicine· 2013Q1· Clinical trial
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- 1,784citations
- Q1SCImago
- 2013year
Short summary
A 12-week sofosbuvir-based regimen achieved a 90% sustained virologic response rate in previously untreated patients with Hepatitis C genotypes 1, 4, 5, or 6. In a separate trial, sofosbuvir plus ribavirin was non-inferior to standard therapy for genotypes 2 or 3, with fewer adverse events.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hepatology
HepatologyMedicine